These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 24523328)

  • 1. [Correction of dyslipidemia in patients with chronic hepatitis C, combined with diabetes type 2].
    Derbak M; Boldizhar P
    Georgian Med News; 2014 Jan; (226):25-31. PubMed ID: 24523328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes.
    Mihm S
    Dig Dis; 2010; 28(1):280-4. PubMed ID: 20460924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
    Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ; Lee SD
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose abnormalities in hepatitis C virus infection.
    Huang JF; Yu ML; Dai CY; Chuang WL
    Kaohsiung J Med Sci; 2013 Feb; 29(2):61-8. PubMed ID: 23347806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon].
    Porcaro G; Sannino C; Mastroianni M; Ciavattone A; Bartiromo D; Nascia S
    Minerva Med; 2000; 91(7-8):141-5. PubMed ID: 11155462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C and diabetes: one treatment for two diseases?
    Pattullo V; Heathcote J
    Liver Int; 2010 Mar; 30(3):356-64. PubMed ID: 20040049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific phenotype associated with diabetes mellitus secondary to chronic hepatitis C infection.
    Poussier A; Lebouvier M; Penfornis A; Di Martino V; Buffier P; Verges B; Hillon P; Petit JM
    Diabet Med; 2008 Oct; 25(10):1237-40. PubMed ID: 19046205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
    Harris K; Smith L
    Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic hepatitis and cholangitis. The liver at risk].
    MMW Fortschr Med; 1999 Jun; 141(25):20-1. PubMed ID: 10897899
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients.
    Imazeki F; Yokosuka O; Fukai K; Kanda T; Kojima H; Saisho H
    Liver Int; 2008 Mar; 28(3):355-62. PubMed ID: 18290778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does telaprevir possess a direct antidiabetic effect?
    Tallón de Lara P; Himschoot T; Frossard JL; Negro F
    Liver Int; 2014 Jul; 34(6):967-9. PubMed ID: 24329983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon versus interferon and UDCA combined therapy in chronic hepatitis C.
    Mazur W; Machniak M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
    Med Sci Monit; 2001 May; 7 Suppl 1():157-64. PubMed ID: 12211712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study].
    Buzzelli G; Moscarella S; Focardi G; Dattolo P; Giusti A; Calviani L; Relli P; Gentilini P
    Minerva Med; 1992 Sep; 83(9):537-40. PubMed ID: 1436604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of effectively treated chronic hepatitis C infection in the development of type 2 diabetes mellitus.
    Purnak T
    Hepatology; 2009 Jun; 49(6):2131-2; author reply 2132. PubMed ID: 19437495
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA; Mansurova FKh
    Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.